Sugi Predict

Sugi Predict / Compounds / SCHEMBL310317

SCHEMBL310317

SCHEMBL310317

NC(CCC(F)(F)F)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 4/20 0.55
▸ NOS3 P29474 3/20 0.55
▸ NOS1 P29475 3/20 0.55
▸ GSR P00390 2/20 0.52
▸ GRM8 O00222 1/20 0.52
▸ GRM6 O15303 1/20 0.52
▸ GRIN2D O15399 1/20 0.52
▸ GRIN3B O60391 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ GRIK1 P39086 1/20 0.52
▸ GRM5 P41594 1/20 0.52
▸ GRIA1 P42261 1/20 0.52
▸ GRIA2 P42262 1/20 0.52
▸ GRIA3 P42263 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ GRIA4 P48058 1/20 0.52
▸ GRIN1 Q05586 1/20 0.52
▸ GRIN2A Q12879 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888856 1.00 NOS2 (0.55) NOS2NOS3NOS1GSRGRM8
SCHEMBL310316 1.00 NOS2 (0.55) NOS2NOS3NOS1GSRGRM8
Hydrochloric Acid SCHEMBL15240323 0.98 NOS2 (0.56) NOS2NOS3NOS1GSRGRM8
SCHEMBL188384 0.91 GSR (0.56) NOS2NOS3NOS1GSRGRM8
SCHEMBL188383 0.91 GSR (0.56) NOS2NOS3NOS1GSRGRM8
SCHEMBL18762553 0.91 GSR (0.56) NOS2NOS3NOS1GSRGRM8
Hydrochloric Acid SCHEMBL15665490 0.89 GSR (0.54) NOS2NOS3NOS1GSRGRM8
Hydrochloric Acid SCHEMBL15665491 0.89 GSR (0.54) NOS2NOS3NOS1GSRGRM8
SCHEMBL18791051 0.87 GSR (0.57) NOS2NOS3NOS1GSRGRM8
SCHEMBL18774896 0.87 GSR (0.57) NOS2NOS3NOS1GSRGRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012106579-A1 AMINO ACID DEHYDROGENASE AND ITS USE IN PREPARING AMINO ACIDS FROM KETO ACIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-09 — — WO claimed
CN-1455663-A Novel aerosol formulation containing polar fluorinated molecule ASTRAZENECA AB (SE) 2003-11-12 — — CN claimed
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 — — US claimed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 — — EP claimed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 — — WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2026-02-05 — — US disclosed
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-08-05 — — US disclosed
EP-3615019-B1 MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION NAVITOR PHARM INC (US) 2025-06-04 — — EP disclosed
EP-4556069-A2 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2025-05-21 — — EP disclosed
WO-2025099047-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) BICYCLETX LIMITED (GB) 2025-05-15 — — WO disclosed
US-20250074938-A1 CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-03-06 — — US disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed
US-5276137-A Enkephalin derivatives THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1994-01-04 — — US disclosed
EP-0206460-B1 L-PHENYLALANINE DEHYDROGENASE AND USE THEREOF SAGAMI CHEMICAL RESEARCH CENTER (JP) 1993-08-11 — — EP disclosed
EP-0513872-A1 L-phenylalanine dehydrogenase and use thereof SAGAMI CHEMICAL RESEARCH CENTER (JP) 1992-11-19 — — EP disclosed
EP-0353211-A1 New compounds Aktiebolaget Hässle (SE) 1990-01-31 — — EP disclosed
US-4849345-A L-phenylalanine dehydrogenase and use thereof SAGAMI CHEMICAL RESEARCH CENTER (JP) 1989-07-18 — — US disclosed
EP-0206460-A2 L-phenylalanine dehydrogenase and use thereof SAGAMI CHEMICAL RESEARCH CENTER (JP) 1986-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074938-A1 CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES ACE, TMPRSS2, ACE2 NOS2 3063/4885NOS3 2981/4885NOS1 2749/4885
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF RICTOR, RPTOR, MTOR NOS2 223/4885NOS3 1282/4885NOS1 758/4885
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 NOS2 1608/4885NOS3 2146/4885NOS1 2946/4885
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 NOS2 1608/4885NOS3 2146/4885NOS1 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.